---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007710"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:32:07.787425+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xenetic extends Scripps collaboration with $400k funding for DNase platform

## Summary
- Extended Research Funding & Option Agreement with Scripps Research by 12 months; total funding up to ~$400,000.
- Initial $65k payment on Nov 1, 2024, followed by ~$65k monthly payments over 5 months.
- Focus: systemic DNase I combined with CAR T-cell therapies for hematological cancers and melanoma.
- Xenetic holds option to acquire exclusive license to new IP from the DNase research program.
- Advancing DNase oncology platform toward Phase 1 for pancreatic carcinoma and solid tumors.

## SEC filing metadata
- accession: 0001683168-24-007710
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316824007710/0001683168-24-007710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316824007710/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007710
- JSON: https://secwatch.observer/filing/0001683168-24-007710.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007710.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.